Skip to main content

Table 1 Study design

From: Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study

Study design characteristics

Description of characteristics

Population

AD and mixed dementia patients with hyperlipidaemia

Outcome

MMSE points

Statistical model

Linear mixed-effects regression models with inverse probability of drop out weighting

Medication use

Time-updated exposure

• Primary analysis: average DDD during the 6-month period preceding index date

• Secondary analysis: yes/no use of medication during the 6-month period preceding index date

Analysis

Primary:

1. Statin users vs non-users of statins

Secondary:

2. Simvastatin vs atorvastatin users

3. Simvastatin vs rosuvastatin users

4. 1Lipophilic vs 2hydrophilic statins users

5. 3Fungal vs 4synthetic statins users

6. Non-statin lipid lowering medication users vs statin users

Covariates

Age, gender, diagnosis year, residency, care unit, comedications, comorbidities

Stratified analyses

1) Gender, 2) age (split at mean age at index date)

Sensitivity analyses

1) Multiple imputations of MMSE, 2) incident users

  1. Patients with AD and mixed dementia who had hyperlipidaemia were included in the study. Outcome was cognitive decline, evaluated with MMSE points. Linear mixed-effects regression models with inverse probability of drop out weighting were used.
  2. Main analysis included comparison of statin users to non-users of statins which included information on average defined daily dose (DDD) of statins in the 6-month period preceding index date.
  3. Secondary analyses consisted of comparisons between simvastatin vs atorvastatin, simvastatin vs rosuvastatin users, lipophilic vs hydrophilic statin users, fungal vs synthetic statin users and non-statin lipid lowering medication users vs statin users, using a dichotomous (yes/no) use of medications in the 6-month period preceding index date.
  4. All analysis was stratified on gender and mean age of the cohort at index date (79.5 years). Sensitivity analysis included multiple imputations of MMSE and incident users.
  5. 1Lipophilic statins: simvastatin, atorvastatin, fluvastatin
  6. 2Hydrophilic statins users: pravastatin, rosuvastatin
  7. 3Fungal statins (type 1): lovastatin, pravastatin, simvastatin
  8. 4Synthetic statins (type 2): atorvastatin, fluvastatin, rosuvastatin